HIGH COURT OF AUSTRALIA
GORDON A-CJ,
EDELMAN, STEWARD, JAGOT AND BEECH‑JONES JJ
COMMONWEALTH OF AUSTRALIA APPELLANT
AND
SANOFI (FORMERLY SANOFI-AVENTIS) & ORS RESPONDENTS
Commonwealth of Australia v Sanofi
[2024] HCA 47
Date of Hearing: 4 & 5 September 2024
Date of Judgment: 11 December 2024S169/2023
ORDER
Appeal dismissed with costs.
On appeal from the Federal Court of Australia
Representation
J T Gleeson SC and F T Roughley SC with G Watson Keesing and M F Caristo for the appellant (instructed by Corrs Chambers Westgarth)
J C Sheahan KC with J J Hutton SC, S Fitzpatrick and B K Lim for the respondents (instructed by Jones Day)
Notice: This copy of the Court's Reasons for Judgment is subject to formal revision prior to publication in the Commonwealth Law Reports.
GORDON A-CJ, EDELMAN AND STEWARD JJ.
Introduction
The important point of law in this appeal is to reaffirm the limited circumstances in which this Court should review findings of fact made by a primary judge, which were not disturbed by the intermediate appellate court. The principled approach taken by this Court, reaffirmed in these reasons, is common to many ultimate appellate courts in the common law tradition. That principle is that, absent special or exceptional circumstances such as plain injustice or clear error, this Court will not engage in a detailed review of concurrent factual findings of lower courts. This approach applies a fortiori to concurrent findings of facts and counter-facts that are made as steps towards an ultimate finding of facts. The principle is a pragmatic one based upon an important need for triage. For every appeal that is heard by an ultimate appellate court, with a limited capacity to hear appeals, another appeal (or, as in this case, sometimes more) will not be heard.
This appeal does not concern any individual rights, nor expose any plain injustice or clear error.
The first respondent, which collectively with the other respondents may be described as "Sanofi", held a patent in a number of jurisdictions including Australia in respect of the drug clopidogrel which is usually prescribed to patients who have suffered, or are at risk of suffering, a heart attack or stroke. Sanofi earned annual worldwide revenue from sales of clopidogrel equivalent to more than $1 billion. Clopidogrel had been supplied by Sanofi in Australia in tablet form since 1998 and it was first listed on the Pharmaceutical Benefits Scheme ("PBS") on 1 November 1999.
The Apotex group of companies was at all material times a substantial manufacturer and distributor of generic medicines worldwide. It developed a generic clopidogrel product which it sought to bring to market in Australia. On 25 September 2007, Sanofi gave the usual undertaking as to damages in support of an interlocutory injunction granted by Gyles J of the Federal Court of Australia that prevented Apotex Pty Ltd ("Apotex" or "Apotex Australia") from competing with Sanofi by manufacture and sale of a generic competitor to Sanofi's patented drug, clopidogrel.…
Keep reading for free
Create a free CaseChat account to read Commonwealth of Australia v Sanofi and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] HCA 47
- Decision Date
CaseChat Overview and Summary
The High Court was required to determine the standard of review applicable to concurrent findings of fact by lower courts, particularly when an ultimate appellate court is asked to disturb such findings. The Court also considered the onus of proof in relation to loss arising from an undertaking as to damages, and whether the Commonwealth had discharged its onus in proving that the generic products would have been listed on the PBS but for the interlocutory injunction.
The Court applied the well-established principle that an ultimate appellate court should not disturb concurrent findings of fact by lower courts in the absence of special or exceptional circumstances, such as plain injustice or clear error. The Court noted that the Commonwealth's appeal did not meet this standard, as it did not concern individual rights, injustice, or clearly wrong findings. The Court found that the Commonwealth had not demonstrated that the lower courts made clear errors or caused plain injustice by failing to address its case on its merits. The Court also indicated that the Commonwealth had not discharged its onus of proof regarding the counter-factual scenario of PBS listing.
The appeal was dismissed with costs.
Orders
Orders of the court
Appeal dismissed with costs.
Background
Background to the litigation
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.